The EQ-5D-3L Valuation Study in Pakistan.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
22
08
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
To utilize EQ-5D in economic evaluations, a societal-based value set is needed. To date, no value sets exist for any EQ-5D instrument in Pakistan. Previous EQ-5D studies conducted in Pakistan 'borrowed' health preferences developed in other countries. However, for a value set to be valid for Pakistani population, it should represent the preferences of the Pakistani population, and culture and living standards of Pakistan. The aim of this study was to derive a Pakistani EQ-5D-3L value set. A moderately representative sample aged 18 years and over was recruited from the Pakistani general population. A multi-stage stratified quota method with respect to ethnicity, gender, age and religion was utilized. Two elicitation techniques, the composite time trade-off (cTTO) and discrete choice experiments (DCE) were applied. Interviews were undertaken by trained interviewers using computer-assisted face-to-face interviews with the EuroQol Portable Valuation Technology (EQ-PVT) platform. To estimate the value set, a hybrid regression model combining cTTO and DCE data was used. A total of 289 respondents who completed the interviews were included for the analysis. The hybrid model correcting for heteroskedasticity without a constant was selected as the final model for the value set. It is shown that being unable to do usual activities (level 3) was assigned the largest weight, followed by mobility level 3, self-care level 3, pain/discomfort level 3 and anxiety/depression level 3. The worst health state was assigned the value - 0.171 in the final model. A Pakistani country-specific EQ-5D-3L value set is now available. The availability of this value set may help promote and facilitate health economic evaluations and health-related quality-of-life (HRQoL) research in Pakistan.
Sections du résumé
BACKGROUND
BACKGROUND
To utilize EQ-5D in economic evaluations, a societal-based value set is needed. To date, no value sets exist for any EQ-5D instrument in Pakistan. Previous EQ-5D studies conducted in Pakistan 'borrowed' health preferences developed in other countries. However, for a value set to be valid for Pakistani population, it should represent the preferences of the Pakistani population, and culture and living standards of Pakistan.
OBJECTIVE
OBJECTIVE
The aim of this study was to derive a Pakistani EQ-5D-3L value set.
METHODS
METHODS
A moderately representative sample aged 18 years and over was recruited from the Pakistani general population. A multi-stage stratified quota method with respect to ethnicity, gender, age and religion was utilized. Two elicitation techniques, the composite time trade-off (cTTO) and discrete choice experiments (DCE) were applied. Interviews were undertaken by trained interviewers using computer-assisted face-to-face interviews with the EuroQol Portable Valuation Technology (EQ-PVT) platform. To estimate the value set, a hybrid regression model combining cTTO and DCE data was used.
RESULTS
RESULTS
A total of 289 respondents who completed the interviews were included for the analysis. The hybrid model correcting for heteroskedasticity without a constant was selected as the final model for the value set. It is shown that being unable to do usual activities (level 3) was assigned the largest weight, followed by mobility level 3, self-care level 3, pain/discomfort level 3 and anxiety/depression level 3. The worst health state was assigned the value - 0.171 in the final model.
CONCLUSIONS
CONCLUSIONS
A Pakistani country-specific EQ-5D-3L value set is now available. The availability of this value set may help promote and facilitate health economic evaluations and health-related quality-of-life (HRQoL) research in Pakistan.
Identifiants
pubmed: 37702988
doi: 10.1007/s41669-023-00437-8
pii: 10.1007/s41669-023-00437-8
doi:
Types de publication
Journal Article
Langues
eng
Pagination
963-974Subventions
Organisme : euroqol
ID : EQ project 20180660
Informations de copyright
© 2023. The Author(s).
Références
Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.
doi: 10.1016/0168-8510(96)00822-6
pubmed: 10158943
Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, Busschbach J, Boye KS. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245–57. https://doi.org/10.1007/s10198-020-01195-8 .
doi: 10.1007/s10198-020-01195-8
pubmed: 32514643
pmcid: 7561556
Rencz F, Gulácsi L, Drummond M, Golicki D, Prevolnik Rupel V, Simon J, Stolk EA, Brodszky V, Baji P, Závada J, Petrova G, Rotar A, Péntek M. EQ-5D in Central and Eastern Europe: 2000–2015. Qual Life Res. 2016;25(11):2693–710. https://doi.org/10.1007/s11136-016-1375-6 .
doi: 10.1007/s11136-016-1375-6
pubmed: 27472992
Kaur G, et al. Criteria used for priority-setting for public health resource allocation in low-and middle-income countries: a systematic review. Int J Technol Assess Health Care. 2019;35(6):474–83.
doi: 10.1017/S0266462319000473
pubmed: 31307561
Tarn Y-H, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health. 2008;11:S137–55.
doi: 10.1111/j.1524-4733.2008.00378.x
pubmed: 18387058
Malik MA, Iqbal SP, Abrejo F. Nature, scope and use of economic evaluation of healthcare programmes: with special reference to Pakistan. JPMA. 2017;67(5):773.
Rehman GU, Shi H. ABO and Rh (D) blood groups distribution in Pakistan: a systematic review. Forensic Res Criminol Int J. 2020;8:237–44.
Shaikh BT, et al. Resource allocation in Pakistan’s health sector: a critical appraisal and a path toward the Millennium Development Goals. World Health Popul. 2013;14(3):22–31.
doi: 10.12927/whp.2013.23438
pubmed: 23803492
Pattanaphesaj J, et al. The EQ-5D-5L valuation study in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):551–8.
doi: 10.1080/14737167.2018.1494574
pubmed: 29958008
Devlin NJ, et al. Valuing health-related quality of life: an EQ-5 D-5 L value set for England. Health Econ. 2018;27(1):7–22.
doi: 10.1002/hec.3564
pubmed: 28833869
Malik M, et al. A pilot study of valuation methods of the EQ-5D and the impact of literacy, cultural and religious factors on preferences. Value Health Reg Issues. 2022;30:48–58.
doi: 10.1016/j.vhri.2021.10.003
pubmed: 35144144
Stolk E, Ludwig K, Rand K, van Hout B, Ramos-Goñi JM. Overview, update, and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value Health. 2019;22(1):23–30. https://doi.org/10.1016/j.jval.2018.05.010 .
doi: 10.1016/j.jval.2018.05.010
pubmed: 30661630
Stolk EA, et al. Discrete choice modeling for the quantification of health states: the case of the EQ-5D. Value Health. 2010;13(8):1005–13.
doi: 10.1111/j.1524-4733.2010.00783.x
pubmed: 20825618
Janssen BM, et al. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14(Suppl 1):S5-13.
doi: 10.1007/s10198-013-0503-2
pubmed: 23900660
Chan KKW, Pullenayegum EM. The theoretical relationship between sample size and expected predictive precision for EQ-5D valuation studies: a mathematical exploration and simulation study. Med Decis Mak. 2020;40:339–47. https://doi.org/10.1177/0272989x20915452 .
doi: 10.1177/0272989x20915452
Hansen TM, Stavem K, Rand K. Sample size and model prediction accuracy in EQ-5D-5L valuations studies: expected out-of-sample accuracy based on resampling with different sample sizes and alternative model specifications. MDM Policy Pract. 2022;7(1):23814683221083840. https://doi.org/10.1177/23814683221083839 .
doi: 10.1177/23814683221083839
pubmed: 35281553
pmcid: 8905070
Ramos-Goñi JM, et al. Quality control process for EQ-5D-5L valuation studies. Value Health. 2017;20(3):466–73.
doi: 10.1016/j.jval.2016.10.012
pubmed: 28292492
Ramos-Goñi JM, et al. Valuation and modeling of EQ-5D-5L health states using a hybrid approach. Medical care. 2017;55(7):e51.
Omelyanovskiy V, et al. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997–2007.
doi: 10.1007/s11136-021-02804-6
pubmed: 33713323
pmcid: 8233249
Khabibullina A, Gerry CJ. Valuing health states in Russia: a first feasibility study. Value Health Reg Issues. 2019;19:75–80.
doi: 10.1016/j.vhri.2019.01.005
pubmed: 31181452
Yusof FA, Goh A, Azmi S. Estimating an EQ-5D value set for Malaysia using time trade-off and visual analogue scale methods. Value Health. 2012;15(1 Suppl):S85-90.
doi: 10.1016/j.jval.2011.11.024
pubmed: 22265073
Chemli J, et al. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L. Qual Life Res. 2021;30(5):1445–55.
doi: 10.1007/s11136-020-02730-z
pubmed: 33447958
pmcid: 8068700
Leidl R, Reitmeir P. An experience-based value set for the EQ-5D-5L in Germany. Value Health. 2017;20(8):1150–6.
doi: 10.1016/j.jval.2017.04.019
pubmed: 28964448
Luo N, et al. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharmacoeconomics. 2014;32(5):495–507.
doi: 10.1007/s40273-014-0142-1
pubmed: 24519603
Prevolnik Rupel V, Srakar A, Rand K. Valuation of EQ-5D-3l health states in Slovenia: VAS based and TTO based value sets. Zdr Varst. 2020;59(1):8–17.
pubmed: 32952698
pmcid: 7478084
Rencz F, et al. Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary. Value Health. 2020;23(9):1235–45.
doi: 10.1016/j.jval.2020.03.019
pubmed: 32940242
Zhuo L, et al. Time trade-off value set for EQ-5D-3L based on a nationally representative Chinese population survey. Value Health. 2018;21(11):1330–7.
doi: 10.1016/j.jval.2018.04.1370
pubmed: 30442281
Yang Z, et al. Selecting health states for EQ-5D-3L valuation studies: statistical considerations matter. Value Health. 2018;21(4):456–61.
doi: 10.1016/j.jval.2017.09.001
pubmed: 29680103